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In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat,
today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide,
thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are
on the rise, a development that has been associated with environmental and lifestyle changes accompanying the
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continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert
research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment
of this most prevalent chronic disease of the 21st century.
The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the
field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all
with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways
Diseases Patients’ Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary
Disorder (COPD) patients’ organizations. In support of their missions, the present EAACI Position Paper, in
collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key
recommendations for future research funding at the national and European levels.
Although allergies may involve almost every organ of the body and an array of diverse external factors act as
triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic
diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs.
Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical
syndromes into more coherent, uniform and treatment-responsive groups. Research efforts to unveil the basic
pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the
pathophysiologic complexity of allergies will allow for the design of novel patient-oriented diagnostic and
treatment protocols. Several allergic diseases require well-controlled epidemiological description and surveillance,
using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for
extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of
modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally,
particular attention should be paid to the difficult-to-manage, precarious and costly severe disease forms and/or
exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals,
hold great promise for targeted and causal management of allergic conditions. Active involvement of all
stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized
herein.
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Allergies represent the most frequent chronic diseases in
Europe today, affecting, with the most conservative esti-
mates, the daily lives of more than 60 million people.
While at the beginning of the 20th century, allergies were
viewed as rare diseases, the last few decades have seen a
dramatic increase in disease burden. The industrial and
technological revolution has led to environmental changes,
including climate variation, pollution and microbial steri-
lization, but also to an urban, sedentary life style, affecting
on one hand the intensity, type and diversity of external
exposures, while on the other hand altering the normal
immune/inflammatory responses.
Allergies involve almost every organ of the body in vari-
able combinations with a broad spectrum of possible
symptoms, and thus their manifestations cover a wide
range of phenotypes. Studies in Europe have shown that
up to 30% of the population suffers from allergic rhino-
conjunctivitis, while up to 20% suffer from asthma and
15% from allergic skin conditions [1,2]. These numbers
match those reported for other parts of the world, such as
the USA and Australia. Food allergies, are becoming morefrequent and severe; occupational allergies, drug allergies
and allergies to insect stings (occasionally fatal), further
aggravate the burden of the allergy epidemic. In contrast
to the popular belief that allergies are mild conditions, a
considerable and increasing proportion of patients (15%-
20%) have severe, debilitating disease and are under
constant fear of death from a possible asthma attack or
anaphylactic shock [3]. Within the EU, there are neverthe-
less wide geographical variations in the incidence of aller-
gies with a south to north and east to west gradient [4,5].
An alarming observation is that most allergic conditions
start in childhood and peak during highly productive years
of individuals, with allergic rhinitis affecting up to 45% of
20–40 year old Europeans. The numbers may even be an
underestimation, as many patients do not report their
symptoms or are not properly diagnosed. Indeed, it is esti-
mated that approximately 45% of patients have never
received a diagnosis [6]. Notwithstanding evidence sug-
gesting a plateau in some areas, the European Academy of
Allergy and Clinical Immunology (EAACI) warns that in
less than 15 years more than half of the European popula-
tion will suffer from some type of allergy!
Papadopoulos et al. Clinical and Translational Allergy 2012, 2:21 Page 3 of 23
http://www.ctajournal.com/content/2/1/21Major knowledge gaps in allergy
 Causes of allergy, as well as reasons for recent
increase in prevalence are unknown
 The natural history, including mechanisms of
spontaneous resolution, are unknown
 There is marginal understanding of interactions
among microbes, immune system and allergic
disorders
 Therapeutic targets with potential for a complete
cure are scarce
Independent of incidence, age group or nationality, it
is important to realize that allergic diseases have a detri-
mental impact on the quality of life of patients and their
families, affecting their personal development, career
plans and lifestyle choices. Allergies may affect sleep and
mood, school or work competence, and social inter-
action [7]. For example 43% of patients with allergic rhi-
noconjunctivitis have sleep disturbances and 39% have
difficulty in falling asleep [6]. The possibility of failing
an examination increases by 40%-70% in school-age
children with rhinitis [6]. Allergic individuals have a
higher risk of developing depression [7]. The impact of
allergies on quality of life can be as high or even higher
than that of diseases commonly perceived as being more
‘serious’ [6,8].
At the society level, the rising prevalence of allergic
diseases poses a multifaceted, major socioeconomic bur-
den on national and European budgets. The increased
use of health services, hospitalization and pharmaceut-
ical costs, in addition to the billions of days of lost product-
ivity through absenteeism or presenteeism (people going
to work but being unable to perform), reveal a worrying
prospect for public health when it comes to allergies [9]. It
is estimated that the annual cost of asthma in Europe is
over €18 billion [8]; allergic rhinitis may cost several times
more (up to €100 billion, according to unpublished data
from the Global Allergy and Asthma Network of Excel-
lence, GA2LEN, investigators). Skin allergy care costs may
be as high as that of asthma [10,11]. Given the nature
of current lifestyles, the ageing population and continu-
ing environmental changes, these numbers are likely to
increase, unless a concerted effort is devised to under-
stand the causes and mechanisms of allergy and design
effective strategies for prevention and/or treatment.
Special attention should be paid to childhood allergies
as these usually demonstrate a persistent and varying
course: many children first develop eczema, followed by
asthma and allergic rhinitis, the so called “allergic
march”. Therefore, early diagnosis and adequate control
of allergy is crucial especially for children. The Polish
Presidency of the Council of the EU underlined this prob-
lem in its conclusions on “Prevention, early diagnosis andtreatment of chronic respiratory diseases in children”
(unanimously adopted by the EU Ministers of Health in
December 2011) [12].
EAACI is the leading professional organization in the
field; its members are nearly 8000 physicians, research-
ers and academicians, as well as all of the European
National Allergy Societies. EAACI is dedicated to
improving the health of people affected by allergic dis-
eases by promoting adequate patient care, advancing
basic and clinical research and encouraging education
and training. The European Federation of Allergy and
Airways Diseases Patients’ Associations (EFA) is a non-
profit network of allergy, asthma and chronic obstruc-
tive pulmonary disorder (COPD) patients’ organizations,
representing 35 national associations in 22 countries
and over 400,000 patients. EFA is dedicated to making
Europe a place where people with allergies, asthma and
COPD have the right to the best quality of care, a safe
environment, the right to live uncompromised lives and
be actively involved in all decisions influencing their
health. More information about the organizations and
their programs can be found at www.eaaci.org and www.
efanet.org.
Following their missions, EAACI and EFA, advocate
for feasible, sustainable and patient-centered strategies for
allergy research. There is currently a great need for a sus-
tained investment in allergy research. Key mechanisms
need to be further understood. Several important find-
ings at the basic immunological level are close to being
translated into bedside treatments. New preventative
approaches require large-scale studies to be confirmed so
that they can be used for public health purposes.
This article, written by Section and Interest Group
Board members of EAACI and co-authored by EFA,
intends to create a milestone, describing the current re-
search needs in the wide spectrum of allergic diseases,
and provide key recommendations to provide input for
consultations on current and future research programs
at the national and European levels. By prioritizing vari-
ous projects of basic, translational and clinical allergy
research, and efficient networking, such programs may
not only yield ground-breaking results, but also crucially
inform patient and public health strategies, reducing
health-related costs and improving the quality of life of
millions in Europe and around the world, while provid-
ing opportunities for a strong European Research Area
and an innovative knowledge-based European industry.
They can also inform novel National Plans following the
model of the Finnish Asthma and Allergy Programs [13]
, implementing wide stakeholder participation.
Objectives and methodology
The aim of this article is to briefly describe the current
understanding of the whole spectrum of allergic diseases
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gaps amenable to research at the national and European
levels. Input was obtained by all EAACI Sections and
Interest Groups; the Chair, Secretary and Board Mem-
bers of each group prepared a paragraph related to their
specific domain. EFA was also consulted and provided
input to the text. These were subsequently integrated
and reviewed by the EAACI Executive Committee
members, who provided by consensus a concluding part
and summary of key points.
Understanding the allergy epidemic
Epidemiology
Research needs in the epidemiology of allergy
 Europe-wide epidemiological studies on
occupational allergy, drug allergy, venom
hypersensitivity, exposure to various environmental
agents
 Interactions between various risk factors of allergy
development to explain prevalence differences
 Link between sensitization and clinical allergy
development
 Incidence, prevalence studies of various disease
phenotypes and endotypes
 Development of pan-European registries
Epidemiology is the study of health and disease in
populations. Several landmark studies have defined the
global burden of allergic diseases, and have demon-
strated that the problem is growing. Major demographic,
socio-economic and environmental developments such
as urbanization, globalization, upcoming economies
(BRIC countries) and climate change will most likely
contribute to further increases. The International Study
of Asthma and Allergies in Childhood (ISAAC) reports
that well over 20% of children in European countries
suffer from an allergic disease at some point during their
childhood [14]. This study also assessed allergy preva-
lence sequentially and observed a rise in prevalence
especially in areas where allergic diseases were previ-
ously less common [2]. Large-scale population-based
data from the European Community Respiratory Health
Survey (ECRHS) [15] and the Global Allergy and
Asthma Network of Excellence (GA2LEN) [16] clearly
show that allergic diseases are significant health pro-
blems in adults too. A similar initiative for food allergy
(EuroPrevall) [17], has been recently completed, but
population-based information is currently lacking for
occupational allergy, drug and insect venom hypersensi-
tivity, as well as daily exposures to environmental agents
such as pollutants and cosmetics. These studies have
revealed significant differences in allergy prevalence
even amongst those of the same ethnic background,advocating that, notwithstanding the importance of
genetic factors, environmental factors are likely to be
responsible for the observed prevalence gradients and
time trends. Socio-economic background, family size,
urban dwelling, farm exposure, infection history, diet,
obesity, use of certain drugs, tobacco smoke exposure
and indoor and outdoor air pollution are among the
factors associated with atopic disease.
In spite of these clear indications, we are currently
missing studies that aim at explaining the prevalence
differences and trends between populations taking all
known risk factors into account as well as the interac-
tions between risk factors (including gene-environment
interactions). Rapid developments in the field of infor-
mation technologies allowing systems approaches now
offer the opportunity to study these complex issues in a
comprehensive way.
When it comes to allergies, it is vital to maintain an
open mind about the nature of causal influences and be
prepared to follow up clues or signals emerging even in,
at first sight, unlikely places: for instance, the protective
effect of Alpine farms has been an important stimulus to
aetiological enquiry [18]. In addition, the link between
allergic sensitization and clinical allergy remains poorly
understood and new molecular methods may shed
further light on this fundamental issue.
One limitation of large population-based studies has
been the use of questionnaires in the diagnosis of
asthma or allergic rhinitis and that more objective
markers, such as spirometry and bronchial hyper
responsiveness, do not capture the episodic nature of
the disease and often do not correspond to the clinical
phenotype. An advantage in atopic dermatitis is that
the skin is readily accessible to examination. The strong
association between clinical atopic dermatitis and filag-
grin skin barrier gene mutation carriage has opened up
new avenues to explore gene-environment interactions,
not only in the context of atopic dermatitis, but also
allergic respiratory disease and food allergy [19].
Another important area of epidemiological research is
the application of epidemiological methods to explore
the quality and safety of medical care provided for
patients with allergic diseases, for instance through
establishing registries with a main focus on the efficacy
and safety of treatments, such as immunotherapy,
systemic immunosuppressive drugs and biologicals. Regis-
tries should also capture trends in disease prevalence and
severity and differences between age and/or social groups.
Data on emerging allergens, including work-related expos-
ure, could also be monitored.
Overall, we need to find better ways of identifying the
phenotypes of allergic disease, using standardized meth-
odology between studies to facilitate direct comparabil-
ity. This will then allow us to revisit known and hitherto
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longitudinal population-based cohorts that take into
account environmental, genetic and immunological fac-
tors (biomarkers) as well as the fluctuant nature of aller-
gic diseases and disease severity. Novel approaches to
genetic and gene-environmental interaction studies will
be helpful to identify the ‘missing heritability’.
Immunology, molecular and cellular mechanisms
Major gaps in understanding the allergic immune response
 Immunological basis of allergy epidemic
 Innate immune response to molecules that are
coexposed with allergens
 Role of novel subsets of T cells, B cells and innate
lymphoid cells in allergy development
 Epithelial barrier function and its role in allergy
development and chronicity
 Mechanisms of development of immune tolerance
to allergens and novel ways to induce this
 Understanding epigenetic regulation of the allergic
inflammation
 Development of novel biologicals to treat allergy
 Identification of novel biomarkers for endotyping
patients for the prediction of treatment response
and prognosis
 Development of immunological registries and
Europe-wide disease-specific biobanks
In diseases involving the immune system such as al-
lergy, autoimmunity, transplantation rejection, cancer
and infections, antigens are either the direct or indirect
cause of the disease and can be targeted for treatment
[20]. The investigation of what makes a protein an aller-
gen has been a prerequisite of understanding allergic
disease to develop strategies for immune intervention.
Allergens are almost always proteins, but not all proteins
are allergens. A protein with allergenic activity should
display two properties a) induction of IgE response,
which involves the sensitization phase including T cell,
B cell and dendritic cell cooperation, and b) induction
of a clinical response to the same or similar protein on
subsequent exposures, which involves immediate and
late phase responses [21]. Many allergens contain potent
stimulatory properties for the epithelium, such as the
protease activity of house dust mite. Besides proteases
and oxidases, extracts of pollen contain low molecular
weight molecules such as pollen-associated lipid media-
tors or adenosine exhibiting a potential to stimulate and
modulate immune cells [22]. Therefore, when exposed
to e.g. pollen, it is more than just allergenic proteins
that we inhale. More knowledge on the immune stimula-
tory properties (adjuvant-like activity) of allergens, in
addition to their antigenic potential will be of greatimportance and might help in modifying allergens in the
application of allergen specific immunotherapy.
An increasing body of evidence indicates that immune
responses in allergy involve a comprehensive network
of cellular and molecular interactions (Figure 1). Novel
insights from implicated environmental influences on
the development of allergy have increased interest in
innate immune responses preceding and directing the
adaptive immune response. In parallel, we have now
identified a role of the local tissue immune response, not
only in determining the implication of a specific tissue
in allergy (i.e. atopic asthma vs. atopic dermatitis) but
also the role of structural cells such as epithelial cells in
the innate immune responses to environmental triggers,
including allergens.
As a direct result of epidemiological findings of
reduced incidence of allergy in farm environments,
and many others on the so-called hygiene hypothesis,
there has been interest in the development of early and
innate immune responses. Pattern recognition receptors
such as Toll like receptors (TLR) are important in these
reactions, essentially deciding over the pro- or anti-
inflammatory nature of subsequent adaptive immune
responses. It is becoming clear that these receptors
do not only play a role on innate immune cells direct-
ing their response to e.g. lipopolysaccharide, double
stranded RNA or bacterial DNA, but also on tissue cells
such as epithelial cells or keratinocytes [25]. Very
recently, a novel category of innate lymphoid cells with
still a wide variety of names, such as nuocytes, lymphoid
tissue–inducer cells (LTi cells) or innate lymphoid cells
(ILCs) have been described. The demonstration of IL-13
and IL-5 production by so-called type-2 ILCs in allergic
inflamed tissue is a strong hint that these cells can have
an important role in the Th2-type skewing in allergic
tissues, even in the absence of direct involvement of
antigens [26]. The epithelial cells at environmental inter-
faces (skin, respiratory tract and gut mucosae) are also
important for allergy development, possibly through
reduced barrier function and/or the inherent properties
of epithelial cells to induce Th2 responses [27]. There is
increasing evidence that the composition of the micro-
biota of the gut (and possibly of the airways or even
skin) play an important role in deciding over develop-
ment towards allergy or protection against it [28]. The
epigenetic regulation of allergic inflammation rendering
certain genes or gene areas more accessible to transla-
tion should be extensively studied and is expected to
provide better links to the influence of the environmen-
tal changes. Also, multigenerational epigenetic memory
can help us to explain the inherited influence of the
environmental exposure [29].
In addition to the almost classical definition of T
helper cells in Th1 and Th2, many more T cell subsets
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Figure 1 Mechanisms of allergic inflammation in asthma. Epithelial cell activation by allergens, viruses, bacteria and pollutants takes place
and their proinflammatory cytokines and chemokines induce inflammation and contribute to Th2 response with TNF-α, IL-13, TSLP, IL-31, IL-33.
Th2 response involves multiple cytokines such as IL-4, IL-5, IL-9, IL-13, IL-25, IL-33, eosinophilia, and local and systemic IgE production. A series of
chemokines are produced and migration of inflammatory cells to the allergic tissues takes place. In addition, other effector T cell subsets, such as
Th9, Th17 and Th22 cells play inflammatory roles. Cross-linking of IgE receptor FcεRI on the surface of mast cells and basophils and their
degranulation, induces a type 1 allergic response. The activation of smooth muscle cells, myofibroblasts, angiogenesis and subepithelial fibrosis,
lead to remodeling. Bronchial hyperreactivity takes place, with enhanced susceptibility to bronchoconstriction. Innate lymphoid cells may
contribute to many aspects of allergic inflammation by the help of multiple cytokines. Epithelial apoptosis and shedding are essential in the
mechanisms of eczema and asthma [23,24]. Survival and reactivation of migrating inflammatory cells and their interaction with resident tissue
cells and other inflammatory cells augment allergic inflammation.
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cells, Th17, Th9 and Th22 cells [30-33]. Moreover, for
all T cell subsets it is evident that their role can differ in
different tissue types. Accordingly, there is increasing
evidence that differentiated Th cell populations can alter
the range of cytokines they produce, indicating a certain
degree of “cell plasticity”. Understanding the molecular
basis of the process through which cells modify their
cytokine-producing potential is likely to provide interest-
ing insights that may allow the development of strategies
to alter Th cell function in immune-mediated patholo-
gies, including allergic diseases. Amongst T-cell subsets,
it is becoming clearer that CD8 T cells, classically called
cytotoxic T cells, contain potent immunomodulatorysubsets, which may be potent in the release of several
cytokines, including IL-13. In addition, the immune
regulatory and immune suppressive roles of various T
and B cell subsets, such as T regulatory cells and B regu-
latory cells still remain to be elucidated.
In many inflammatory diseases, application of biologi-
cals is an important option in treating severe forms of
the disease. It is surprising that there is only limited po-
tential of the known biologicals developed specifically
for allergy [34]. Anti-IgE has major IgE decreasing
effects, but is only indicated in a small subset of allergic
asthmatics [35] at present although licensing studies for
chronic urticaria are in an advanced stage. Blocking
eosinophil differentiation and activation by anti-IL-5 is
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suggest the need for identifying responsive populations.
The outcome of the application of these agents has indi-
cated that our knowledge of the immunological mechan-
isms responsible for allergic inflammatory diseases
remains incomplete. Although improved forms of anti-
IgE or blocking of IL-5 effects may provide better drug
efficacy, it is also important to design new biologicals
and find novel application of established ones. Com-
bined application of allergen-specific immunotherapy
(SIT) with anti-IgE treatment, might improve safety and
efficacy of immunotherapy.
SIT is the only treatment that alters the immuno-
logical basis of the disease. The immune responses to
allergen observed during SIT are being described at
increasing level of detail, but there is a continuous
debate around mechanisms of induction and mainten-
ance of tolerance. It is absolutely essential to further
elucidate the immune mechanism of SIT. Only in this
way new leads can be found to transform SIT from a
therapy requiring “chronic administration” for years in a
row into an effective therapeutic vaccination based on
a small number of shots, and perhaps even a preventive
vaccination [34].
Evidence is gathering that the complex interplay
between the innate and adaptive immune response both
of the myeloid and lymphoid lineages, in combination
with the immune response of the tissue ultimately deter-
mines the development and expression of allergic dis-
eases. A further important issue comprises adjuvant
factors from the allergen carriers. We face an interest-
ing and challenging era that will implicate all novel
immunological insights in understanding better the
immune-pathophysiological mechanisms in allergic dis-
eases. This will lead to improved insight in the disease
itself and also in new treatment options that may even
result in allergy prevention, which is a major concern
not only for parents thinking about their children, but
for society as a whole.
Diagnostics
Next steps in allergy diagnosis
 Improvement of molecular diagnostics methods
 Diagnosis of biomarkers for endotyping
 Easy and standardized tests for cellular diagnosis
 Development of point of care assays and devices
 Development of tests for endotyping, follow up of
exacerbations and treatment response
The challenges in allergy diagnosis lie in developing
methods that are objective, rapid, reproducible, cost-
effective, sensitive and specific for the disease. They need
to be able to identify exposures and contribute todecision making for treatment, preferably also in pri-
mary care. In addition, tests monitoring the response to
treatment and allowing the comparison of preclinical
and clinical effects across large cohorts and in several
countries are needed. As recombinant molecular therap-
ies are becoming available, there is a need to tailor treat-
ment to disease burden, phenotype and/or endotype
more effectively, which has always been a key request by
patient groups; in this respect improved allergy diagnosis
is a prerequisite. Molecular diagnostic methods enable
a much more detailed analysis of the allergen mole-
cules and their association with clinical presentations.
Molecular approaches have great potential to signifi-
cantly improve the prognostic value of diagnostic tests,
but large-scale clinical studies are needed for their valid-
ation. Both allergen molecules and recombinant anti-
bodies are made available to enlarge the repertoire
of diagnostic tests [37]. The first allergen molecule-
based multiplex tests have reached the market [38], sig-
nificantly increasing diagnostic and epidemiological
options [39].
Improvement and standardization of cellular tests,
such as the basophil activation test, [40] will enable
laboratories to more closely monitor disease status and
advance allergy diagnosis and monitoring from the mere
assay of IgE affinity, concentration and avidity to an
integrated evaluation of the burden of allergic disease on
the individual. Such an approach is not feasible at the
moment. A similar methodology to the one used to
produce standardized T cell tests, should be adopted.
The involvement of reference centers and standardized
comparisons of efficacy can lead to standardized meth-
ods of analysis. In combination with molecular tools,
this will enable improved-resolution diagnosis with a
higher prognostic value, which in turn will result
into more precise diagnosis and superior monitoring of
allergic disease. Recent advances in multicolor flow-
cytometry are expected to contribute to cellular diagno-
sis and disease phenotyping/endotyping. In addition,
detection of recently discovered microRNAs and/or exo-
somes in body fluids may open new ways for non-
invasive diagnosis and monitoring of patients. Develop-
ment of a standardized mast cell line similar to resident
tissue mast cells would revolutionize the understanding
and diagnosis of mast cell-mediated immediate hyper-
sensitivity reactions.
In the diagnosis of drug allergy, cellular tests can be
more useful both for diagnosis of type I allergy [41] and for
diagnosis of the more severe type IV allergy [42]. As treat-
ment options expand and life expectancy increases, people
will require more frequent medical treatment and ex vivo
diagnostic approaches will become more important.
Ex vivo tests for type I allergy will play a role in both
the diagnosis of occupational allergy and food allergy.
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paediatric allergy, since they constitute an alternative to
allergen exposure tests currently considered as the gold
standard in diagnosis of allergy.
In the near future, individualized –omics analyses will
provide a wealth of detailed information.
A new integrated approach, combining data of genomics
(genome-wide SNP association studies) and metabolomics
with disease-specific proteome and transcriptome data
from biopsies and body fluids (blood, saliva, nasal lavage)
will allow a comprehensive characterization of complex
diseases for the first time. Furthermore, diagnostic tools
to characterize the environment such as microbiome,
pollen counts, mite counts, allergen quantification, mould
counts, smoke, and other pollutants need to be developed
and standardized across Europe.
In addition to diagnostic approaches based on large
laboratory-intensive methods, individualized point of
care testing should be developed as this can/will remove
a burden from the health sector with patients even-
tually capable of partly monitoring their own allergic
disease and optimizing their treatment in order to
rely more on a predefined plan and electronic support
(ICT and e-health) and less on frequent visits to the
allergy clinic.
Patient-reported outcomes
Patient-reported outcomes (PROs) refers to all health-
related reports coming from the patient, without in-
volvement or interpretation by physician or others [43]
(i.e. Health Related Quality of Life (HRQoL), symptoms,
illness perception, satisfaction, well-being, perceived dis-
ease control).
PROs recently gained great attention in clinical re-
search and by regulatory bodies due to their importance
in the overall treatment efficacy assessment [44-46].
The role of patient’s perspectives is now underlined by
the GRADE system [47], which also includes patients’
preferences and values as cornerstones in the process of
formulating recommendations towards diagnostic and
therapeutic interventions, thereby contributing to the
translation of scientific research into real life.
A critical aspect in the management of allergic dis-
eases is their impact on subjective experience. Available
data show that, from the patients’ perspective, allergy is
more than just an annoying disease: when compared to
healthy subjects, patients with asthma, rhinitis, chronic
urticaria, atopic dermatitis and food allergy reported
markedly reduced HRQoL [48]. The burden of the dis-
ease, besides functional and practical problems, includes
some emotional aspects: the presence of a chronic con-
dition, the need to take medication and change habits
and lifestyle may cause anxiety, tension and irritability
and an unsatisfactory social life.Among PROs, HRQoL and patient-reported symptoms
have been extensively evaluated in asthma and rhinitis
[49,50], and more recently, also in chronic urticaria and
food allergy [51].
In contrast to the advanced stage of research in
respiratory and skin allergy, little is known about
HRQoL in allergic conditions such as drug hypersensi-
tivity, occupational allergy and insect venom allergy.
Although some evidence about subjective view of
allergic diseases and their treatment has been achieved,
further unmet needs and unexplored areas should be
underlined. First, there is a need to develop clinical trials
in which PROs are the primary or co-primary outcome.
Another point is the necessity to assess patients’ view-
point with a rigorous methodological procedure (use of
validated tools, correct administration of the question-
naires and report of complete results).
Furthermore, there is a need to reach a global picture
of patient’s perspective about allergy and its treatment by
exploring the following uncovered areas: other PROs
(satisfaction, preferences, well-being, illness perception)
besides HRQoL; burden of comorbidity on PROs; spe-
cific population (children, adolescents, elderly, parents of
allergic children); relation of PROs with other clinical
measures of health impact; relationships among different
PROs and between PROs and psychological variables.
Overall, there is a need for a more correct and exten-
sive assessment of PROs, both in clinical trials and in
routine practice, to capture information unavailable from
other sources, which is crucial for predicting health out-
comes, for establishing health policy and for the optimal
management of allergic diseases.
Age-specific tools for patient information, education
and peer support, major objectives of patient organiza-
tions, should be further developed.
Chronic Respiratory Allergies
In the last decade, it has been clearly demonstrated that
allergies of the respiratory tract (asthma and rhinitis)
very frequently coexist in the same patient, have similar
epidemiology, share mechanisms and interact in terms
of treatment and risk for persistence. Therefore, asthma
and rhinitis are currently considered as part of a com-
mon syndrome, for which different terms, including
‘chronic respiratory allergy’ have been proposed. Add-
itionally, the most common forms of allergic conjunctiv-
itis occur together with rhinitis, in which case, allergic
rhinoconjunctivitis is the prevailing term.
EFA’s 4-year Respiratory Allergies Project ‘Raise
Awareness, Relieve the Burden’ aims at increasing the
awareness of allergy as a serious chronic disease, to re-
ceive earlier concrete diagnosis with proper manage-
ment, to avoid the increase of severity and to relieve the
burden that it may impose on the lives of affected people.
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Awareness, Relieve the Burden’ in 15 languages and
launched a “Call to Action” at the European Parliament
(EP) to call upon policy makers to act in this crucial
topic [6].
Asthma
Asthma is a major global health problem contributing
greatly to socio-economic burden: more than 200 mil-
lion people of all ages suffer from asthma worldwide
[52], and 250,000 people die prematurely every year
due to asthma. Although the majority of patients with
asthma can potentially be sufficiently controlled using
currently available treatments, present management
practices have considerable limitations in a relatively
small, but important subgroup of patients with severe
asthma, who suffer from ongoing symptoms, frequent
exacerbations and reduced quality of life, despite receiv-
ing the best available treatment. So, although this patient
group comprises about ~10% of the overall asthmatic
population, it accounts for more than 75% of the costs
attributable to asthma. Already in 2003, the total cost of
asthma in Europe was calculated at 17.7 billion EUR per
year, and productivity lost to patients’ poor control of
their asthma was estimated at 9.8 billion EUR per
annum [8]. The necessity to improve the management of
asthma has frequently been underlined [53].
Major unmet needs in chronic respiratory allergies
 Mechanisms and management of severe cases
 Characterization of phenotypes and identification of
novel biomarkers for endotypes
 Devise a consensus definition for severe asthma and
exacerbations
 Identification of factors increasing the risk of asthma
exacerbations and preventing them
 Vaccine development against viruses that trigger
exacerbations and severity
 Patient-tailored treatment
 Development of biologicals
 Establish European registry and biobank for
respiratory allergies in meticulously phenotyped
patients
An additional significant unresolved problem in the
management of asthma is the failure to prevent and/or
promptly treat asthma exacerbations, which are asso-
ciated with significant morbidity, risk of death and high
treatment cost [54] and whose prevention in children
may reduce the risk of subsequent adulthood asthma
[55] (Figure 2). Identifying the factors increasing the risk
of asthma exacerbations and designing novel treatments
that reduce the risk are key priorities. Virus infectionshave a major role in asthma exacerbations and pre-
ventive vaccines or passive immunizations are awaited
to prevent virus infection-induced exacerbations. In
addition, to allow for a rational approach to the manage-
ment of asthma, we must consider the emerging evi-
dence for pathophysiological heterogeneity of the
disease, particularly in its more severe forms. The con-
ceptual framework of asthma endo/phenotypes devel-
oped by the EAACI [56,57] can offer the basis for an
improved perception of the pathophysiological mechan-
isms involved in severe asthma and asthma exacerba-
tions and enable target identification and development
of novel treatments. Prediction of the outcomes and
personalization of treatment through innovative
approaches and new technologies can contribute to an
effective intervention in terms of prevention and reduc-
tion of healthcare costs, with improved quality of life for
asthma patients [58]. So, asthma research should aim to
implement a consensus definition of severe asthma and
asthma exacerbations that could usefully guide treat-
ment and match this with diagnostic tools for “scoring”
the asthma patient in terms of disease severity and
future risk for the use in primary care. The recognition
of asthma as a heterogeneous disease is a prerequisite
for planning studies aimed at differentiating between dif-
ferent endo/phenotypes and the sequential creation of
robust clinically-relevant and endo/phenotype-specific
biomarkers and therapies targeting specific pathophysi-
ology, including longitudinal outcomes. In this effort,
we must also identify relevant environmental factors
and the influence of current and prior medication.
The accomplishment of the above aims also necessit-
ates the establishment of large Research Tissue Banks
(including DNA, serum, lavage fluids and other bio-
logical samples) in meticulously clinically phenotyped
patients and the execution of clinical studies to improve
the evidence-base, since most randomized, controlled
trials to date have been carried out in highly selected
patients; we should now aim for effectiveness, rather
than efficacy studies.
Rhinitis
Allergic rhinitis affects up to one third of the adult
population, hence having a major socio-economic im-
pact. In spite of the high prevalence of the disease and
the availability of effective and safe treatments [59], a
significant number of patients remain deprived of an ac-
curate diagnosis and specific anti-allergic treatment [60],
while another group of patients remain symptomatic in
spite of adequate medical therapy [61].
There is a need for the better characterization of the
different phenotypes of allergic rhinitis, which should
be matched with improved understanding of both
the environmental and occupational factors determining
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Figure 2 Pathophysiology of asthma at steady state and during an exacerbation. The airways of asthmatic individuals are characterized by
pathological changes, including thickened basement membrane, collagen deposition and hypertrophic smooth muscle, collectively called ‘airway
remodeling’. Inflammation is triggered by a variety of factors, including allergens and respiratory viruses. These factors also induce hyperreactive
responses in the asthmatic airways, associated with mucus and cell debris released into the lumen, oedema and bronchoconstriction, leading to
airway obstruction and related acute exacerbations. Although pathophysiological changes related to asthma are generally reversible, recovery
may be partial.
Papadopoulos et al. Clinical and Translational Allergy 2012, 2:21 Page 10 of 23
http://www.ctajournal.com/content/2/1/21severity of disease and the endogenous and exogenous
factors that contribute to the progression from rhinitis
to asthma in childhood and adolescence. In this respect,
we must also define control of the disease, through im-
proving insights into the mechanisms underlying uncon-
trolled allergic rhinitis. The similarities and differences
between rhinitis and asthma should be further character-
ized [62]. Diagnosis-wise, there is a need for objective
evaluation tools of disease severity and impact [63].
Treatment-wise, we need to both define patient-related
reasons for undertreatment, reasons for underdiagnosis
and non-compliance of patients to treatment and there-
fore design patient-oriented treatment strategies for
optimal efficacy of treatment and compliance to therapy
[64]. One aspect, which also requires attention, is the
role of complimentary/alternative medicine in allergic
rhinitis, an approach that is widely used and is a com-
mon question from patients.Ocular allergies
Ocular allergies have been studied to a lesser extent,
compared to other allergies. The evaluation of preva-
lence and severity range of ocular allergies in Europe
requires additional effort. The more serious forms, such
as allergic keratoconjunctivitis (AKC), one of the most
serious complications of atopic dermatitis, and vernal
keratoconjunctivitis (VKC), which may have serious
ocular complications such as keratoconus, cataract and
retinal detachment, are of particular interest. Pharma-
cological and immunological research is needed to evalu-
ate new possibilities in modifying the ocular immune
response in these diseases. Although evidence on ocular
immunopathology is available, no comprehensive solu-
tion exists.
The roles of allergens and cross-reactivity, as well as
criteria for consequent immunotherapy, are well estab-
lished in seasonal allergic rhinoconjunctivitis, but far
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Phenotyping and genotyping of these diseases is needed.
This will allow us to effectively choose treatments
(pharmacological and/or allergen immunotherapy).
Furthermore, evidence-based recommendations for use
of available treatment options in ocular allergy are needed.
Dermatological allergies
The skin plays a major role in allergy by acting as the
first frontier of the body to allergen contact and
sensitization. An intact epidermal barrier protects the
immune system from exposure to exogenous allergens,
whilst an impairment of the skin barrier, either mechan-
ically or functionally, allows allergen penetration into
the sub-epidermal layer and promotes sensitization. The
skin as route of sensitization is no longer seen as neces-
sarily being limited to allergy of the skin, but is more
and more considered as a route of sensitization for
allergy involving other organs.
The atopic march starts in newborn skin. The role of
skin integrity and skin microbiota in childhood as inter-
ventional targets to prevent atopic sensitizations should
be studied in large-scale studies with well-defined popu-
lations [65]. The role of allergen avoidance versus early
allergen ingestion in promoting tolerance versus
sensitization to food allergens and subsequent atopic
symptoms must be evaluated [66]. The possibilities of
tolerance induction to prevent symptoms caused by food
allergens for both children and adults should be studied
in more depth, with new monitoring methodologies.
There is an opportunity to study the effect of newer bio-
logical drugs on prevention of the atopic march.
Major unmet needs in skin allergy
 Identification of molecular, genetic and
environmental determinants of the atopic march
 Targeting skin barrier function for novel treatments
and prevention
 Role of skin microbiota and colonizing pathogens
 Better characterization and identification of novel
biomarkers for endotypes
 Monitor new contact sensitizers and promote patch
testing
 Develop and evaluate new drug classes including
biologicals
 Epidemiological monitoring of urticaria and
hereditary angioedema
Atopic dermatitis is one of the most common chronic
inflammatory skin diseases with an estimated prevalence
of 20% in children and 5% in adults [67,68]. The direct
and indirect costs of atopic dermatitis are significant and
comparable to other common chronic diseases withlarge annual economic burdens. However, compared to
psoriasis, the most closely analogous complex inflamma-
tory skin disease, treatment options are limited. There is
a need for new classes of drugs, such as biologicals for
treating it, including those targeting the immune system,
skin barrier, and skin microbiota. Developing methods
for improving the skin barrier function should be an
important focus of future research [69]. It is increasingly
clear from advances in molecular genetics that a close
interaction and reciprocal regulation of epithelial func-
tion by immunological events underlie allergic disease,
and epithelial barrier function is becoming more and
more important in other forms of allergic diseases,
such as asthma and rhinitis [70]. A bench to bedside
approach is necessary to identify the key elements of
these interactions systematically.
Allergic contact dermatitis is one of the most common
work-related diseases and is of appreciable public health
importance because of its significant economic impact.
As knowledge on its diagnostics through patch testing is
waning, promoting patch test education is a paramount
issue. New contact sensitizers continue to appear [71]
and older ones become important in new situations,
emphasizing the need to monitor their appearance in
Europe and worldwide and integrate new knowledge to
relevant regulations at all levels. Contact allergy in chil-
dren continues to be underdiagnosed and should be
studied, tested and publicized more often. The potential
role of food chemicals as a possible cause of dermatitis
and food allergy requires study and, conversely, exposure
to shared haptens in cosmetics and food could poten-
tially be a cause of food allergies [72]. Increasing expos-
ure to palladium, with its high sensitizing potential, in
electronic appliances, dental alloys, jewellery and car
exhaust catalytic converters, presents a real risk of it
becoming the ‘metal allergy of the 21st century’ [73]. The
epidemiology and dynamics of palladium sensitization
call for an in depth study of palladium allergy from the
scientific viewpoint and further regulation of its use.
Urticaria in all its presentations has an estimated life-
time prevalence of around 20% [74]. However, reliable
epidemiologic data are scarce, and most of the published
literature deals with adults. Thus, there is a need for
epidemiological research into urticaria, as well as good
diagnostic markers defining the subgroups within urti-
caria patients. In addition, treatment with new classes of
drugs, including novel antihistamines, mast cell stabiliz-
ing drugs and biologicals, such as omalizumab [75],
should be evaluated thoroughly for their clinical effect-
iveness and understanding the biology of mast cell dis-
ease. Development of specific mediator antagonists for
hereditary angioedema and cryopyrin associated periodic
fever syndrome will help to define the phenotype of
specific subsets of disease.
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Aerobiology and pollution
Airborne allergens are a major trigger of allergic dis-
eases, especially of the respiratory tract. Monitoring of
biological airborne particles (pollen and moulds) is cur-
rently done by private networks. All over Europe, these
national networks are underfunded and on the verge of
collapse. In addition, European Union (EU)-citizens and
scientists have limited access to pollen and mould data
due to diffuse property rights, as most stations are
funded with private money.
Therefore, there is an urgent need to secure, harmonize
and open the existing networks with a European-scale
pollen, allergen and air pollution/air quality forecasting
network, also capable of predicting future developments
in migration of allergenic plants (like Ambrosia artemisii-
folia), and the environmental change in allergen exposure
due to climate change. Thus, we will be able to suffi-
ciently serve allergic sufferers and policy makers. The
existing networks could be incorporated in the Global
Monitoring for Environment and Security (GMES) Net-
work for air quality monitoring and forecasting, in com-
bination with the modeling communities.
Major unmet needs in aerobiology
 Harmonization of existing networks for monitoring
biological airbourne particles
 Monitoring of the ‘exposome’ in conjunction with
epidemiology in sensitization and symptom
monitoring
 Identification of the socioeconomic burden of
different biological airbourne particles to define
strategies to fight pollution
 Identification of the role of climate change in
allergic diseases
 Epigenetics studies to link the environmental factors
with inherited inflammatory thresholds
The causes of allergic diseases are multifaceted. Thus,
multiple exposure monitoring (‘exposome’) in conjunc-
tion with symptom and sensitization monitoring may
reveal novel associations and interactions. Assessment of
the ‘exposome’ (biological and chemical, indoor and out-
door) EU-wide, in concert with ongoing epidemiological
studies/registries of allergic symptoms and sensitizations,
will produce important synergies [76]. The climate
change and its impact on development of allergies,
microbiota, virus epidemics, parasites, moulds and food
resources should be specifically focused on [77].
Pollen, moulds, parasites, viruses and bacteria are the
carriers of allergens and/or innate immune system dan-
ger signals. These biological properties (not the pollen
or the mould but the allergen and the danger signal) inambient air are currently only partly monitored and
should be an addition to current research. Cross border
comparison, also with non-EU countries will enlarge
the biological variance and thus facilitate the finding of
allergy modulating factors [78,79].
Infections and allergy
Major research gaps on the role of infections in allergy
 Differential immune response to various
microorganisms
 Helminth infections as a paradigm to prevent/
treat allergy
 Evolution and dynamics of the microbiome
 Viral-bacterial interactions
 Development of vaccination and other targeted
interventions against human rhinoviruses
 Determine mechanisms underlying deficient antiviral
immune responses in asthma
Both infections and commensal micro-organisms have
a crucial role in the development and severity of allergic
disorders and are involved in their resolution or chron-
icity. To harness their properties for prevention and
treatment of allergies, we need to better understand
which micro-organisms affect allergies naturally and
how they interact with immune and inflammatory
responses in allergy. This requires considerable epi-
demiological, clinical and mechanistic research both in
human and animal models.
Helminth infections are associated with reduced skin
prick test responsiveness to environmental allergens, es-
pecially if the parasite burden is high and occurs in early
life. The evidence with regard to allergic disease is more
heterogeneous, but some studies show a negative rela-
tionship between allergy and certain parasite infections,
such as hookworm and schistosomiasis [80]. However,
clinical trials treating people with established allergy
with a single parasite dose have not shown bene-
ficial effects so far. Future research will need to include
trials of multi-dose administration resulting in higher
worm burden and stronger immunomodulation. Ano-
ther approach could be to develop allergy therapies and
prophylaxis based on parasite-derived products; such
products should be assessed for efficacy and safety, espe-
cially in young children, who are likely targets for pri-
mary prevention of allergy [81].
There is also emerging evidence that exposure to both
commensal and pathogenic bacteria may influence the
development of allergy [82]. We need to understand in
detail how the microbiomes of gut, skin, and airways
evolve from early life to senescence, which factors (e.g.
birth mode, breastfeeding, diet, puberty, pregnancy,
infections) influence their composition and how this
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studies will also contribute to investigations aiming at
the development of preventive and therapeutic applica-
tions of pre-, pro- and symbiotics.
During the last decades, it has become evident that
viral infections, particularly those caused by human rhi-
noviruses (RV) are the most frequent triggers of acute
exacerbations of asthma; in some cases viral agents have
been detected in more than 90% of such events [83,84].
RVs are also responsible for the majority of mild rhinitis,
i.e. common colds, therefore contributing further to
symptoms in respiratory allergic patients. Viral bron-
chiolitis in infants is associated with an increased asthma
risk. Once again RVs appear to be the agents most
strongly associated, with a remarkable 40-fold increase
of risk of wheezing at age 6 after an early symptomatic
RV infection [85]. Whether early life episodes of respira-
tory viral infections also predispose to the induction of
sensitization is less well-established, but has potentially
great impact on strategies for allergy prevention. Given
the lack of effective treatment or prevention of virus-
induced asthma symptoms, future research must focus
on developing diagnostic, therapeutic and prophylactic
modalities for virus induced respiratory allergy. Our
incomplete understanding of the role that respiratory
viruses play in immune and inflammatory responses of
the respiratory tract, their regulation and resolution,
requires research in both animal models and in well-
defined patient populations [86]. This needs to include
studies to determine mechanisms underlying deficient
antiviral immune responses reported in asthma [87]
and define the roles of interactions between different
viruses, including the recently identified rhinovirus-C
[88], viral-bacterial synergistic effects, which accentuate
airway inflammation [89], repeated infections, and inter-
actions between viruses and other factors including aller-
gens and pollutants, in establishing chronic respiratory
allergies. Prospective cohort studies involving compre-
hensive microbiological detection and identification of
other potential triggers of asthma development and
exacerbations may be required to provide accurate infor-
mation on natural microbial exposures and the relative
impact of individual respiratory pathogens.
Insect stings
Hymenoptera, which represent one of the largest orders
of insects, are responsible for the majority of anaphylactic
reactions in adults, of which some are fatal. In Europe,
wasp or bee stings are the most common elicitors
of Hymenoptera venom allergy (HVA) having a great
impact on quality of life in adults, children and their
parents [90]. Population-based studies should establish the
regional frequency of HVA in different European coun-
tries [91]. Identification of the genetic background, and ofthe pathophysiological mechanisms involved in venom
allergic reactions also require further research [92].
Healthcare providers and the public alike will benefit from
proper diagnosis and long-term treatment of this poten-
tially life-threatening allergy. To improve the diagnosis of
HVA, certain techniques such as molecular diagnosis and
peptide microarray immunoassay need further evaluation.
A better knowledge on eliciting allergens might not only
help to make a correct diagnosis but might also help to
optimize venom extracts, or even replace them with re-
combinant allergens, for treatment. Parallel studies should
aim at improving the clinical interpretation of well-
established diagnostic procedures such as the intradermal
tests, baseline serum tryptase concentration and sting
challenge test [93].
Unlike food and medication allergy, which are mana-
ged primarily by allergen avoidance, the prospective
management of HVA relies on venom immunotherapy
(VIT), where treatment is mediated through administra-
tion of gradually increasing doses of the venom-allergen.
The efficacy of VIT in adults has progressed consider-
ably, reaching a protective level of up to 98%. Still, there
are many open questions regarding patient selection for
VIT and duration of treatment. The long-term prognosis
of untreated in comparison to treated HVA in children
and adults needs further evaluation; only few data are
available on risk factors of severe reactions in children
with HVA [94]. Various treatment protocols mainly dif-
fer from each other with respect to the degree of toler-
ance of VIT, and it should be examined whether specific
patients particularly profit from specific types of treat-
ment protocols [95].
Food, diet & nutrition
Food allergies affect a considerable proportion of chil-
dren and adults in Europe and are the leading cause of
severe anaphylaxis [96]. Furthermore, there is increased
recognition of disorders associated with food allergy,
such as eosinophilic oesophagitis.
Our current knowledge about the molecular mechan-
isms and factors for the allergic sensitization and elicit-
ation phase is limited. Therefore, in depth characterization
studies of both allergens and their co-factors are needed
to understand how immune tolerance towards dietary
antigens is disrupted and allergic sensitization initiated.
An integrative approach is needed, that addresses the role
of exposure (timing and dose) and host factors, including
investigations on the role of genetic predisposition, the
extent and composition of the intestinal microbiome and
the involvement of the innate defense system [19,97].
In particular the interplay between the innate immune
system and food should be studied in more detail. While
we know that in spite of a close botanical relationship,
peanut seems to be a strong sensitizer and soy a much
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son for this discrepancy is differences on the allergen
level (including different digestibility), on the level of
innate immune response stimulation, on the level of the
different food matrices, on eating habits (oral exposure)
or even on the level of non-oral exposures such as trans-
dermal or inhalation. Thus both clinical studies of aller-
gen exposure and uptake and in vitro models of the
human intestine by which these features can be studied
should be given high priority.
Unmet needs in food allergy
 Understand molecular mechanisms of tolerance and
its disruption in food allergy
 Improve diagnosis with individual allergen
components, food matrix interactions and threshold
identification
 Establish food allergy phenotypes
 Establish novel immunotherapeutic approaches
 Evaluate the socioeconomic cost of food allergies
 Standardize nutritional interventions
For improved diagnosis of food allergy, complete
panels of well characterized individual allergens and
knowledge on their food matrix interactions regarding
allergenicity, are still lacking. Identification of thresholds
for each individual food is also needed. In component
resolved diagnosis, investigation of allergen specific IgE
recognition with clinical implications and the identifica-
tion of marker allergens is needed at least for the
most important food allergen sources. These well-
characterized diagnostic tools will contribute to patient
tailored dietary recommendations and to design avoid-
ance strategies, accordingly; such approaches have been
initiated within the context of the FP6-funded project
EuroPrevall. On the other hand in depth knowledge of
allergens and certified reference material available for
the food industry will help them to fine tune their aller-
genic risk management. Furthermore, individual food
allergens including their hypoallergenic variants will
contribute to novel immunotherapeutic applications for
food allergy.
Epidemiological and clinical studies suggest that there
are different phenotypes in food allergy and that the
onset (early, late), natural course (short term, persistent),
and clinical presentation (mild, severe) differ. Multicen-
tre studies involving a comprehensive clinical, immuno-
logical and (epi)genetic evaluation are needed to
establish the different phenotypes in food allergy. This
will further guide the management and specific treat-
ment of food allergic patients.
Specific immunotherapy in food allergy, especially oral
but also sublingual, has provided promising results. Withthe availability of hypoallergens, also subcutaneous im-
munotherapy has regained interest [98]. Studies ranging
from basic science to clinical application are urgently
needed regarding indications, underlying immunological
mechanisms, safety, efficacy and cost-effectiveness of
this treatment [98].
Recently, methods were developed to assess and rec-
ord the reduced quality of life of the food allergic pa-
tient. However, the implementation of these findings in
improved dietary recommendations, training of the pa-
tient or production of safer foods is still lacking and calls
for a multidisciplinary approach to address the relevant
issue. In parallel, the socioeconomic cost of food allergy
is largely unknown. Capitalizing on a specific instrument
built in the EuroPrevall project [99], the economic bur-
den of food allergy can be studied across Europe, and
the impact on costs of diagnostic and therapeutic inter-
ventions evaluated.
Despite the importance of diet and nutrition in im-
mune development, only a small number of studies have
evaluated their role on the prevention and natural
course of food allergy and allergic diseases in general.
There is therefore a need for descriptive studies on pre-
ventive nutritional aspects. These would include nutri-
tional analysis around conception, during pregnancy, but
also in early life and evaluation of atopic disease out-
comes longitudinally. Nutritional analysis in lactating
women as related to the composition of breast milk may
also provide important insights. The role of specific
nutrient levels, e.g. vitamin D, should be part of an
extensive nutritional analysis [100].
The influence of the nutritional composition of avoid-
ance diets on both nutritional status, but also disease
severity, of children and adults with food allergy should
be further evaluated [101].
Unlike other diagnostic tools, the removal of a sus-
pected food from the diet has not been properly standar-
dized nor validated. Furthermore, there is an important
diagnostic value of a standardized allergy-focused diet
history. Based on expert consensus opinion, both the
recent NIH US guidelines and the UK NICE guidelines
[102] reported that diet history is the cornerstone of
food allergy diagnosis. Research efforts should gather
evidence to substantiate this opinion, including the
role of the dietitian in both diagnosis and individual
dietary counseling.
Food labeling remains an important issue and EFA is
actively involved in the elaboration and follow-up of the
new EU regulation on food information to consumers.
Drug allergies
Drug hypersensitivity reactions (DHRs) affect more than
7% of the general population and represent an important
public health problem [103]. They are unpredictable,
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medical care and are a major cause of post-marketing
drug withdrawal [104]. While urticaria and maculopap-
ular exanthemas are the most frequent, other drug-
induced reactions, although less frequent may have a
high fatality rate, including systemic anaphylaxis and
toxic epidermal necrolysis (TEN).
DHRs represent a growing health problem and their
world-wide prevalence is expected to increase over the
next decades. A number of reasons will contribute to
this phenomenon and will amplify its impact on the gen-
eral population. First, new pharmacological molecules
are continuously going to the market and more and
more patients will be exposed to these agents. In par-
ticular, biological drugs, such as monoclonal antibodies,
have profound interactions with the immune system and
may cause severe hypersensitivity reactions. Second,
there is an increasing use of over-the-counter medica-
tions that may potentially raise the risk of adverse reac-
tions to drugs because of lack of medical supervision.
Finally, the concomitant administration of multiple
drugs (polychemotherapy), particularly in the elderly, is
expected to increase the rate and severity of reactions to
drugs: It is worth to mention, for example, that aspirin
(ASA) and other drugs widely used for cardiovascular
diseases (ACE inhibitors, beta-blockers) may exacerbate
or aggravate allergic and anaphylactic reactions.
The complexity in DHRs is high; despite the com-
mon occurrence of DHRs, the mechanisms, diagnostic/
therapeutic opportunities and differential diagnoses dif-
fer between drugs and manifestations and experience
towards specific reactions is lacking. Every centre alone,
experiences a limited and mostly biased spectrum of the
disease and physicians frequently do not attempt to clar-
ify a suspected reaction at all [105]. With diversity and
diagnostic challenges, both individual patient phenotyp-
ing and epidemiological studies are affected. Addition-
ally, most therapeutic recommendations, including new
approaches such as desensitization are predominantly
based on case reports or small case series. As we do
not know the natural course of disease, it is not clear
whether lifelong avoidance is really necessary. Taking
into account that DHR research has not been supported
for a long time by either the pharmaceutical industry or
national programs [106], there is a clear need for train-
ing, standardized criteria, and large, multicentre studies
and data collection to provide answers to the above
questions. National and international registries should
also be implemented or potentiated to provide useful
information on the real dimension of the problem and
to identify reliable parameters to assess the individual
risk of DHRs.
New diagnostic tools have to be developed, as the
available ones are poorly validated and may lead tomisclassification (underreporting or overdiagnosis). The
development of new procedures, such as standardiza-
tion of skin tests, test concentrations, advancement and
improvement of diagnostic test agents and tests, such
as basophil activation test (BAT), Elispot, lymphocyte
transformation test (LTT), is indispensable to confirm a
DHR and identify the culprit drug to be avoided in the
future. Existing diagnostic tests must be critically vali-
dated and standard operation procedures should be tai-
lored to specific drugs, specific manifestations and age
groups (children versus adults). Drug re-exposure by
standardized challenges are most needed procedures in
order to limit medication withdrawal based on an unclear
diagnosis. Nevertheless, they are often non-standardized
and lack good correlation with currently used diagnostic
in-vitro tests.Research agenda for drug hypersensitivity
 Training (multiple drugs, complex manifestations
and mechanisms)
 Standardization of test procedures (still not
achieved)
 Development of new diagnostic tools
 Reliable epidemiological data with proven
hypersensitivity
 Clinical multicenter studies on diagnosis and
therapy with well-phenotyped patients
 Mechanistic studies (pharmacological interaction
with immune receptors (PI) concept, genetic
pretesting, risk factors)
The availability of tissue and serum samples from
immune-mediated drug hypersensitivity reaction (IDHR)
patients is a prerequisite for basic research in the
mechanism of DHRs, which may be allergic or non-
allergic, with immunological or pharmacological recog-
nition and with the allergenic determinants mostly
unknown. In this effort, the study of genetic variants,
especially of the major histocompatibility complex
(MHC) molecules, should be included, in order to
enable personalized recommendations for the risk to
develop a DHR. To generate preclinical testing meth-
ods to assess the risk of potential DHRs in new drugs,
research should also encompass the characterization of
drug-specific (chemical structure, metabolites, exposure),
intrinsic (genetics) and extrinsic risk factors (viral infec-
tions, other danger signals), complemented by preclinical
prediction models.
On the socioeconomic level, as in other allergy man-
ifestations, studies should define the impact of DHRs
on the quality of life of patients and their cost on the
health system.
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Allergy and asthma in sports
A moderate physical activity favors health and well-
being whereas a sedentary lifestyle and obesity are asso-
ciated with a higher prevalence of allergic diseases in
both children and adults [107]. Interestingly, however,
an intense physical training, as a stress event, may induce
several changes in immune parameters and response to
environmental agents, which essentially result in an
increased susceptibility to infections and in a preferential
Th2 (allergic) phenotype [108].
Major research gaps on the role of allergy and asthma
in sports
 Describe mechanisms of exercise-induced
bronchoconstriction and identify biomarkers
 Understand the immune derangement after
strenuous exercise
 Therapeutic trials in athletes
 Standardization of specific diagnostic tests
Physical exercise may also play a direct role on target
organs triggering symptoms such as bronchial obstruc-
tion and anaphylaxis. Indeed, allergic diseases, asthma
and exercise-induced bronchoconstriction (EIB) are
present with high and increasing prevalence in athletes,
significantly affecting their health status and perform-
ance and therefore representing a major concern in
Sports Medicine [109]. The necessity therefore in Sports
Allergy research is to describe the mechanisms of EIB,
so as to clarify the clinical relevance and natural course
of this phenotype and also identify markers of epithelial
stress and inflammation. In this line of research, it would
also be feasible to identify putative danger signals of
immune derangement linked to the transient immune
deficiency, which forms the basis for recurrent infections
in elite athletes and is caused by strenuous and contin-
uous training loads. Research efforts recruiting the –
omics approaches should allow understanding of the
impact of acute and chronic exercise as well as any cor-
relation of gender on the immune functions.
With regard to clinical pharmacology in Sports Al-
lergy, this is often extrapolated from data obtained in
the general population, creating a need for randomized
controlled clinical trials solely in athletes. Allergy and
asthma in athletes is underdiagnosed [110] but this
would be remedied if athletes were to be routinely evalu-
ated through a standardized protocol for sensitization
and immune function; such a policy would also allow
improved management of their condition and permit the
accurate study and screening of the effects on physical
performance of anti-allergic and anti-asthmatic drugs
(with special reference to beta-2 agonists). There is aneed for guidelines for the diagnosis and management
of allergic diseases and these should be widely diffused
and applied by Sports physicians, in compliance with
the World Anti-Doping Agency (WADA) rules, in the
adequate management of these clinical pictures [111].
Some special attention should be paid to the usefulness
of different methods of non-specific bronchial provoca-
tions in diagnosis of athletes’ asthma. Since metacholine
provocation does not prove useful in a substantial per-
centage of cases, more comparative research involving
other stimuli is needed in order to create feasible and
unified algorithms to be used in professional athletes.
Occupational allergy
Major research gaps in occupational allergy
 Changes of occupational allergy with time
 Public health impact of occupational allergy
 Monitor allergen exposure at workplaces
Occupational allergy and particularly occupational
asthma can be caused by more than 300 agents and
about 15% of adult-onset asthma can be attributed to
workspace exposures [112,113]. Exposure-specific stud-
ies on occupational asthma have focused on substances
of high and low molecular weight- e.g. flour, enzymes,
isocyanates and latex [114]. While in developing coun-
tries the workforces probably have more extensive occu-
pational exposures than in high-income countries, lower
figures of the occurrence of occupational asthma have
been reported, probably indicating a problem of under-
detection and methodology. In addition, protective
mechanisms described for respiratory allergies (hygiene
hypothesis) may also play a role for occupational aller-
gies. Still, the public health impact and burden to society
related to occupational or work-related asthma have
been scarcely investigated. Assessment of excess burden
of disease due to specific occupational exposure is a use-
ful measure, when there is valid information on popula-
tion exposure and attributable fractions. Changes in the
working conditions and implementation of new sub-
stances lead to the introduction of new allergens in some
workplaces and the onset of new, so far unknown cases
of occupational allergy. However, there is only little
available information on the changes in the pattern of
occupational allergy over time. An objective evaluation of
the time trends in the incidence and causes of immuno-
logical occupational asthma in the EU, using workers'
compensation data or registry-based data would be of
great importance [115-118]. Prevention of occupational
asthma related to a work-sensitizing agent would ideally
be achieved by avoidance of exposure causing immuno-
logical sensitization and subsequent asthma. Especially
apprenticeship is a period of increased risk of developing
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a need for appropriate professional advice to young
adults aiming to reduce unsuitable job choices and pre-
vent impairment from their careers [119]. Different
forms and different steps of prevention exist, like pri-
mary prevention (the ideal form of prevention), where
workers do not become sensitized to agents that can
cause asthma. Since primary prevention is not always
successful, secondary prevention by medical surveillance
has some evidence to support benefit for those working
with common occupational sensitizers. On the other hand
it is necessary to optimize workers’ education and also the
diagnosis and medical management to minimize further
impairment of the airways [120-124]. There is a need to
increase the implementation of airborne allergen quanti-
fication at workplaces to be used as scientific background
e.g. for the discussion of health-based occupational
exposure limits for high molecular weight sensitizers.
Allergic diseases in children
Childhood is a key period as many allergies start early in
life. It is also characterized by a large number of research
needs, mainly due to the lack of reliable evidence to
guide practice that has resulted from the challenges
associated with undertaking paediatric research. We are
still uncertain how to prevent children from developing
allergic diseases. For example, important advances in
our knowledge of genetic associations with allergic dis-
ease, have not clarified the underlying pathological path-
ways, probably because we have yet to understand their
interactions with environmental exposures. We also lack
knowledge on epigenetic mechanisms, now thought to
be important in allergy. A relatively recent hypothesis in
the prevention field is that high dose oral exposure to
food allergens in early infancy may promote the develop-
ment of immunological tolerance [125]. We must await
the results of large, interventional studies to assess the
validity of this hypothesis and it will be important to
explore whether it also holds for aeroallergens, opening
up possibilities for preventive vaccination. Additionally,
with our improved understanding of the infant immune
system, new therapeutic approaches addressing early
immune stimulation and tolerance induction using bac-
terial compounds need further exploration [126].
Important gaps exist in the diagnostic tools that are
available for young patients with possible allergy. In
practice, it is not uncommon to find children with symp-
toms highly suggestive of clinical allergy, but negative al-
lergy skin or blood tests. There is a need to investigate
the potential importance of novel allergens and whether
we can detect the local presence of relevant specific IgE
in relevant end organs in addition to the skin or serum.
Furthermore, our current allergy skin or blood tests fail
to distinguish between clinical allergy and irrelevantsensitization or to identify patients at high risk of severe
allergy mediated reactions [127]. We need a new
improved approach to diagnostic testing to reduce the
need for potentially dangerous provocations challenges
(e.g. food challenges).
Research needs in paediatric allergy
 More studies in children of different ages are
needed, both on the development of allergy and to
evaluate differential responses to treatment
 Large, primary prevention intervention programs to
confirm current hypotheses and reverse the epidemic
 Improved, non-invasive diagnostic tools
 Prevention and/or treatment of asthma exacerbations
 Evaluate the long-term effects of immunotherapy
in children
 Focus on adolescence
Asthma is an important problem in childhood affect-
ing many children and resulting in significant morbidity
[128]. It has been suggested that vitamin D deficiency
may play an important role in the development of
asthma as well as being associated with severe asthma
[129]. Like many findings in paediatric allergy, these are
based on observational data that are very susceptible to
confounding. There is a research need for multi-centre
randomized controlled trials to assess the role of vitamin
D in the development of asthma and/or severe asthma.
Another unmet need in paediatric asthma is the study of
exacerbations, many of which are associated with viral
respiratory tract infections [83]; we also do not currently
have any therapies capable of preventing or treating such
exacerbations. A possible role of early respiratory virus
exposure in facilitating sensitization to allergens requires
attention as well. A further unexplained association
exists between food allergy and severe exacerbations of
asthma [130], which is important particularly as asthma
is also associated with severe allergic reactions to foods.
Severe asthma in childhood, and adult life, is poorly
understood. In an attempt to understand this area, a
novel unbiased “omics” systems biology approach is cur-
rently being used to explore the underlying pathophysio-
logical mechanisms [131]. A similar approach is also
being used in other allergic diseases and both studies
can be expected to highlight many novel pathways that
have the potential to deliver new therapeutic approaches
for allergic disease.
The majority of our therapies for allergic disease only
suppress the disease process while they are taken. The
exception is immunotherapy, which would appear to
have the potential to alter the natural history of allergic
disease in childhood, for example preventing the devel-
opment of asthma in children with hay fever [132].
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in this area is not optimal there is a need for well
designed, double-blind, placebo-controlled studies to
assess the long-term effects of immunotherapy in child-
hood. While such studies are ethically challenging, it is
important to characterize the long-term effects, as this
would substantially alter the perceived cost-effectiveness
and trade-off between efficacy and safety of immuno-
therapy in childhood.
Adolescents and young adults are at higher than
expected risk of morbidity and mortality from both
asthma and food allergy. While this is poorly under-
stood, it may result from the disengagement of adoles-
cent patients from their medical needs as they are
challenged by the usual process of adolescence [133]. It
is also not assisted by the lack of continuity between
paediatric and adult medical care in many countries.
There is a need to develop a better, adolescent-focused
approach to this at risk group to tackle this unmet need
[134] and to develop better transition strategies to ease
the progression from paediatric to adult services.
Causal treatment of allergy: allergen specific
immunotherapy
Allergen specific immunotherapy is the only currently
available medical intervention that has the potential to
affect the natural course of the disease [135]. Accumu-
lating evidence have convincingly shown that in addition
to alleviating symptoms, allergen specific immunother-
apy can improve quality of life, reduce long-term costs
and burden of allergies, and has the potential to change
the course of the disease. Several appropriately designed
and powered clinical trials have proven its good safety
profile and effectiveness in allergic rhinitis, asthma and
venom allergy [59,136,137].
However, there are still important questions to be
answered. The unmet needs of this causal treatment
should be evaluated in an integrated multinational
academic, research, industry and regulatory agencies
effort in Europe. Research should focus on optimizing
clinical and immunological efficacy, safety and compli-
ance, possibly through improved time-schedules. Novel
approaches such as the use of adjuvants, modified aller-
gens and molecular allergen components should be
widely evaluated [138].
Major knowledge gaps in allergen-specific immunotherapy
 Mechanisms of induction and long term
maintenance of allergen tolerance
 Molecular mechanisms of how T-reg cells and B-reg
cells are generated in vivo and how to affect their
life span
 Role of resident tissue cells in immune tolerance Molecular mechanisms of spontaneous healing,
remissions and exacerbations of allergic disease
 Local tissue events during SLIT and epicutaneous
SIT
 Better adjuvants that specifically induce immune
tolerance
 Early biomarkers and predictors to decide to start,
stop and success
 Phase III clinical trial primary outcomes equivalent
to real-life exposure
 Efficient short term and long lasting treatment
modalities
Outcome measures for both clinical trials and routine
clinical practice should be further standardized and vali-
dated. To date, the required primary outcome is real-life
exposure, which by its nature is very poorly standar-
dized. Alternatives are urgently needed, not only because
costs of failed trials due to lack of pollen exposure are a
great financial burden to the sponsor, but perhaps even
more importantly it is not ethical to subject patients to
double-blind, placebo-controlled (DBPC) trials in which
exposure is at best poorly controlled. Another issue
is the dominance of poly-sensitization in clinical trials
conducted for one allergy. Clear indications and guide-
lines, especially in regard to polysensitized patients are
therefore needed. Multi-allergen immunotherapy needs
more supporting data to be validated. The use of surro-
gate antigen challenges in the eye and nose and their
relationship to clinical efficacy of SIT should be evalu-
ated for both, seasonal and perennial allergens. The use
of pollen chambers in dose–response studies has to be
adequately studied. Surrogate allergen challenges should
also be evaluated as an alternative primary outcome for
phase III clinical trials. New modalities of allergen-
applications such as the epicutaneous and the direct
injection of allergens in the lymph node are promising
and need to be further evaluated. The long-term efficacy
and safety of these modalities needs to be confirmed.
In children, there is a need to identify an optimal dose,
dosing frequency and duration. Most importantly how-
ever, long-term efficacy, including the preventive cap-
acity for asthma and new sensitisations, and the safety
profile of allergen specific immunotherapy should be
further addressed in the paediatric population. This will
facilitate the recognition and approval of allergen spe-
cific immunotherapy in children by regulatory national
and international agencies. The demonstration of long-
term efficacy is required for the current mandatory
paediatric investigation plan (PIP) that must accompany
applications for marketing authorization submitted to the
European Medicine Agency (EMA). In addition, a role of
SIT for secondary prevention in already sensitized chil-
dren has been evoked, but requires further evaluation.
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Furthermore, there is a need to perform economic assess-
ments in high-quality prospective and long-term clinical
studies comparing immunotherapy with pharmacotherapy
in real-life practice.
Understanding the mechanisms of immunotherapy
will ultimately lead to advanced, curative treatments
of allergic diseases, therefore research focusing on the
generation, life span and different roles of T-regulatory
cells is needed [34,139]. Furthermore, long-term immune
tolerance and local tissue events should be studied in
detail, in parallel to the understanding of spontaneous
healing, remission and exacerbations of allergic disease.
Specific issues in relation to immune tolerance include
the molecular mechanisms of how T regulatory cells are
generated in vivo, their life span induced by allergen
immunotherapy, whether they have any deleterious roles,
tolerance to tumour antigens and chronic infectious
agents and the role of resident tissue cells [140].
Increased knowledge on tolerance induction may also
lead to strategies for preventive vaccination [141].
Biomarkers able to predict clinical response, treatment
outcome and/or monitor progression of the treatment are
also key to enhance clinical decisions. Any differences in
the mechanisms of high-dose and low-dose allergen spe-
cific immunotherapy need also to be assessed.
Conclusions
The advances in allergy diagnosis, management and
basic science to date have been substantial. There re-
main, nevertheless, many unmet needs as a consequence
of the modern epidemic of allergy. Extensive research is
needed to counteract the consequences for both individ-
ual patients and public health. Despite the variety of
external factors that may trigger allergic reactions, as
well as the pathophysiological complexity of these
chronic diseases, common themes in relation to research
needs arise: phenotyping/endotyping seems to be widely
required in order to arrange or re-arrange clinical syn-
dromes in more coherent and treatment-responsive
groups. Using different –omics approaches in combin-
ation with systems biology and systems medicine appear
promising in this direction. Using these approaches,
patient-tailored management, including gender specific
focusing, may become realistic. The need for epidemio-
logical description or surveillance, including exposome
monitoring, remains in many fields, and real-life, patient-
centered research supported by registries is required.
Basic mechanisms are still incompletely understood,
therefore, any diagnostic, classification or treatment ef-
fort should be supported by attempts to better under-
stand pathophysiology. Allergen components promise
to be the next generation of diagnostic and therapeutic
tools; large-scale studies are required to bring them tothe clinics. Finally, severe disease, co-morbidities and/or
exacerbations over a chronic course, are usually the most
difficult to manage, more costly and dangerous and
therefore require particular attention. Nevertheless, cur-
rently arising treatments, particularly in the fields of im-
munotherapy and biologicals, hold great promise for
targeted and causal management of allergic diseases.
Major research themes in allergy
 Mechanisms
 Prevention
 Epidemiological surveillance - Registries
 Biomarkers for prediction, diagnosis, classification,
treatment response
 Phenotypes / Endotypes
 Severe Disease/Exacerbations
 Novel treatments (biologicals, vaccines, new drugs)
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